Predicted protein targets (top 20)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | CTNNB1 | P35222 | 1/20 | 0.52 |
| ▸ | WNT3A | P56704 | 1/20 | 0.52 |
| ▸ | ENPP2 | Q13822 | 2/20 | 0.50 |
| ▸ | KDM4E | B2RXH2 | 1/20 | 0.50 |
| ▸ | ALDH1A1 | P00352 | 1/20 | 0.50 |
| ▸ | HPGD | P15428 | 1/20 | 0.50 |
| ▸ | HSD17B10 | Q99714 | 1/20 | 0.50 |
| ▸ | CA1 | P00915 | 1/20 | 0.48 |
| ▸ | CA2 | P00918 | 1/20 | 0.48 |
| ▸ | CA9 | Q16790 | 1/20 | 0.48 |
| ▸ | NPC1 | O15118 | 1/20 | 0.48 |
| ▸ | MAPT | P10636 | 1/20 | 0.48 |
| ▸ | RAB9A | P51151 | 1/20 | 0.48 |
| ▸ | FOLH1 | Q04609 | 1/20 | 0.47 |
| ▸ | SLC6A2 | P23975 | 4/20 | 0.46 |
| ▸ | SLC6A4 | P31645 | 4/20 | 0.46 |
| ▸ | SLC6A3 | Q01959 | 4/20 | 0.46 |
| ▸ | PLA2G2A | P14555 | 1/20 | 0.46 |
| ▸ | MAPK14 | Q16539 | 1/20 | 0.45 |
| ▸ | HDAC1 | Q13547 | 1/20 | 0.44 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL2277951 | 0.89 | KDM4E (0.62) | CTNNB1WNT3AENPP2KDM4EALDH1A1 | |
| SCHEMBL16741873 | 0.87 | ENPP2 (0.54) | CTNNB1WNT3AENPP2KDM4EALDH1A1 | |
| SCHEMBL2272259 | 0.84 | LOXL2 (0.52) | CTNNB1WNT3AENPP2NPC1MAPT | |
| SCHEMBL18941260 | 0.83 | NPC1 (0.63) | CTNNB1WNT3ANPC1MAPTRAB9A | |
| SCHEMBL8604113 | 0.81 | CYP17A1 (0.55) | CTNNB1WNT3AENPP2KDM4ECA1 | |
| SCHEMBL30030142 | 0.81 | CYP17A1 (0.55) | CTNNB1WNT3AENPP2KDM4ECA1 | |
| SCHEMBL30791058 | 0.79 | FOLH1 (0.70) | CA1CA2CA9FOLH1PLA2G2A | |
| SCHEMBL70351 | 0.79 | FOLH1 (0.70) | CA1CA2CA9FOLH1PLA2G2A | |
| SCHEMBL18941141 | 0.78 | NPC1 (0.63) | NPC1MAPTRAB9A | |
| SCHEMBL18966712 | 0.78 | MAPT (0.52) | KDM4EALDH1A1HPGDCA1CA2 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 6 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-8455516-B2 | HIV-1 fusion inhibitors and methods | TOURO UNIVERSITY (US) | 2013-06-04 | — | — | US | claimed |
| US-20110190343-A1 | HIV-1 FUSION INHIBITORS AND METHODS | TOURO UNIVERSITY (US) | 2011-08-04 | — | — | US | claimed |
| US-20170166555-A1 | FUNCTIONALISED AND SUBSTITUTED INDOLES AS ANTI-CANCER AGENTS | NOVOGEN LIMITED (AU) | 2017-06-15 | — | — | US | disclosed |
| US-20170166555-A1 | FUNCTIONALISED AND SUBSTITUTED INDOLES AS ANTI-CANCER AGENTS | NOVOGEN LIMITED (AU) | 2017-06-15 | — | — | US | disclosed |
| US-8455516-B2 | HIV-1 fusion inhibitors and methods | TOURO UNIVERSITY (US) | 2013-06-04 | — | — | US | disclosed |
| US-20110190343-A1 | HIV-1 FUSION INHIBITORS AND METHODS | TOURO UNIVERSITY (US) | 2011-08-04 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (2 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20170166555-A1 | FUNCTIONALISED AND SUBSTITUTED INDOLES AS ANTI-CANCER AGENTS | TPM3, TPM4, TNNI3 | CTNNB1 2019/4885WNT3A 3605/4885ENPP2 664/4885 |
| US-20110190343-A1 | HIV-1 FUSION INHIBITORS AND METHODS | FLI1, API5, MAVS | CTNNB1 4379/4885WNT3A 2299/4885ENPP2 4242/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.